Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ENElham NasrollahiSPS Papp

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals Venetoclax lowers infections but shortens overall survival in older AML patients, highlighting treatment choices.

Key Points

  • To compare real-world clinical outcomes of Venetoclax-based therapy versus intensive chemotherapy in older adults with newly diagnosed AML.
  • Conducted a retrospective cohort study using the TriNetX database
  • Included adults aged ≥60 with newly diagnosed AML
  • Propensity score matching performed based on demographics and comorbidities
  • Outcomes measured included mortality, infections, and cytopenic events
  • Venetoclax reduced infections within 60 days (36.5% vs 48.6%; p = 0.0003)
  • Lower rates of antineoplastic-induced pancytopenia (48.4% vs 56.5%; p = 0.0166)
  • No significant differences in 30-day mortality (12.2% vs 14.7%; p = 0.27) or 90-day mortality (28.7% vs 25.5%; p = 0.28)
  • Median overall survival was longer in intensive chemotherapy group (482 vs 246 days; p < 0.0001)

Cite This Study

Nasrollahi et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3dbhttps://doi.org/10.1182/blood-2025-6996
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intensive chemotherapy versus venetoclax–hypomethylating agents therapy for acute myeloid leukemia: A large real-world propensity-matched study.2026
  2. 2Real-world comparative effectiveness of decitabine/cedazuridine plus venetoclax versus azacitidine plus venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.2026
  3. 3Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting2025
  4. 4Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group2024
  5. 5Comparing induction strategies in acute myeloid leukemia: 10-year real-world experience with 7+3 and HMA/venetoclax.2026